Meet Our Supporters

Session supported by Helsinn

Meet the Experts: Optimizing Antiemetic Prophylaxis for New Anticancer Agents: A Comprehensive Approach in Accordance with International Guidelines

Panelists:

• Prof Grazia Arpino (Italy)
• Prof Florian Scotté (France)

Session Description: Interactive discussion between an ADC breast cancer expert and a CINV expert based on a clinical case that will also involve the audience. The objective is to clarify some important aspects around the CINV management with the new anticancer agents, specifically the ADC (antibody drug conjugates), according to the recently updated MASCC ESMO guidelines.

This session is supported by Biocon Biologics

From Acute to Long-Term Safety: How to Manage Emerging Treatments

Agenda:

• Introduction – Prof Florian Scotté (France)
• Neutropenia Related to Immune Checkpoint Inhibitors – Dr Tim Cooksley (United Kingdom)
• Neutropenia: Are We Correctly Using GCSF? – Prof Mahasti Saghatchian (France)
• Long-Term Safety and Monoclonal Antibodies: What Do We Have to Know? – Prof Hope Rugo (USA)
• Panel discussion to follow

Session Description: The session will provide a comprehensive overview of neutropenia management, encompassing current practices as well as advancements in anticancer treatments. It will delve into the challenges posed by Long Term Toxicity, particularly in light of the increased survival rates associated with monoclonal antibody therapies. This emerging survivorship area will prompt important discussions on navigating the complexities of long-term care and quality of life for cancer survivors.

Bridging the Gap: Developing Care for Patients Receiving Antibody-Drug Conjugates supported by Daiichi-Sankyo / AstraZeneca

Agenda:

• Introduction – Prof Florian Scotté, Session Chair (France)
• Laying the Foundations: The Role of ADCs in Metastatic Breast Cancer – Prof Daniele Santini (Italy)
• Constructing Management Strategies for GI Disorders in Patients Receiving ADCs – Dr Matti Aapro (Switzerland)
• Crossing the Divide: Translating Guideline Recommendations to Real-World Patient Care – Dr Grazia Arpino (Italy)
• Panel discussion to follow

Session Description: Interactive session exploring the risk-benefit profile of ADCs in metastatic breast cancer including discussions on common treatment effects and how they can be managed in real-world clinical practice.

Session sponsored by Chugai

Neutropenic Events Associated with New Anticancer Treatments: From Physiopathology to Practice

Agenda:

• Introduction by Session Co-Chairs: Prof Lodovico Balducci (USA), Prof Claire Falandry (France)
• PARP and CDK Inhibitors – Dr Gabriel Antherieu (France)
• Immunotherapy – Dr Vincent Thibaud (France)
• CAR T-cells – Dr Pierre Sesques (France)
• Panel discussion to follow

LEO Pharma-sponsored session

Meet the Experts: Challenging Clinical Scenario in Frail CAT Patients

Panelists:

• Prof Florian Scotté (France)
• Dr Didier Mayeur (France)

Session Description: 

• To shed light on the tailored management of vulnerable patients with CAT for whom the benefit-risk ratio of anticoagulant therapy may be modified.
• To provide advice to optimize anticoagulant treatment and to decide anticoagulant of choice in these clinical scenarios.

This session is supported by Eli Lilly and Co.

Get Ready, Get Set, Prehabilitate! Current Approaches to Lifestyle-Based Prehabilitation Before Cancer Treatment.

Session Chairs: Prof Raymond Chan (Australia), Assoc Prof Nicolas Hart (Australia)

Invited Speakers:
– The State of Science in Multimodal, Multidisciplinary Prehabilitation: What’s Next? – Dr Matthew Wallen (Australia)
– Effects of Multimodal Prehabilitation in Lung Cancer Setting: What’s the Trick? – Dr Francis-Edouard Gravier (France)

This session will include oral proffered papers – to be confirmed.

Session supported by La Roche-Posay

Optimization of Therapeutic Outcomes for Oncology Patients Through Appropriate Skin Care: ISKIMO Expert Consensus

Session Chair: Dr Mario Lacouture (USA)

• Skin Toxicities in Patients Under Oncology Drugs: An Overview – Dr Julie Ryan Wolf (USA)
• How Can DC Improve Patient Outcome? Clinical Study Results – Dr Delphine Kerob (France)
• The Role of Dermocosmetics in the Management of Cancer-Related Skin Toxicities: ISKIMO Expert Consensus – Prof Brigitte Dréno (France)
• A Patient Perspective – Lawrence Stallings
• Panel discussion to follow

Session Description: Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions. During this symposium, our speakers will provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.

Session sponsored by Thermo Fisher Scientific

Meet the Experts: Cancer Patients with New Fever – What Should I Do? Interactive Case-Based Discussion on Management – From the ED to the ICU

Panelist: Dr Stephen Pastores (USA)

Session Description: In this interactive session, you will explore and discuss a comprehensive case study to learn how to effectively optimize the management of cancer patients presenting with a new fever.

Session sponsored by Nestle

Details to follow.